AOD-9604: Evidence, Mechanism, Dosing & Legal Status

AOD-9604 ("anti-obesity drug 9604," also coded LAT8881) is a 16-amino-acid synthetic analog of the lipolytic C-terminal tail of human growth hormone — hGH residues 177-191 plus an N-terminal tyrosine — engineered to stimulate fat breakdown without the IGF-1, growth-promoting or diabetogenic effects of full hGH.1 It is marketed as a "proven fat-loss peptide." Its own clinical record says otherwise. This monograph separates the two.

This article is informational and editorial content for research and educational purposes only. It is not medical advice, not a protocol to follow, and not a sourcing guide. AOD-9604 is not an FDA-approved drug; it is sold as a "research chemical not for human use" and is prohibited in sport. Dosing figures are reported strictly as seen in the published literature for completeness — not as recommendations. Consult a licensed clinician before any health decision.

What is AOD-9604 and how does it work?

AOD-9604 is the C-terminal fragment of human growth hormone spanning residues 177-191 (15 amino acids) with an added N-terminal tyrosine, giving a 16-residue peptide (Tyr-hGH 177-191) cyclized via a disulfide bond between its two cysteines and produced by solid-phase peptide synthesis.2 The extra tyrosine distinguishes it from the closely related hGH 176-191 ("HGH Fragment 176-191"); both share the same purported lipolytic domain.1 The compound was developed at Monash University and commercialized by Metabolic Pharmaceuticals in Australia.3

The proposed mechanism — graded C, preclinical and mechanistic — is that AOD-9604 stimulates lipolysis (fat breakdown) and inhibits lipogenesis (fat synthesis), in part by inhibiting acetyl-CoA carboxylase in hepatocytes and adipocytes and possibly by increasing repressed beta-3-adrenoceptor RNA expression in adipose tissue.2 Critically, it does not stimulate IGF-1 production and is not a high-affinity GH-receptor agonist or antagonist — the fragment was specifically selected to dissociate the fat-metabolism action of GH from its anabolic and diabetogenic actions.2 From a functional, root-cause standpoint the theory is attractive — restore a lipolytic signal suppressed in obesity without GH's metabolic downsides — but the human receptor target remains incompletely defined and the beta-3 mechanism is inferred from animal work, not confirmed in human metabolic studies. More recent work re-frames the molecule (as LAT8881) as a lanthionine synthetase C-like protein (LANCL) activator, a distinct preclinical hypothesis explored for cartilage, neuropathic pain and influenza.14

The pharmacokinetics explain why the original developers chose pills, not injections. AOD-9604 is rapidly cleared — an IV half-life of roughly 3 minutes in pigs versus about 21 minutes for full hGH — yet pig data showed an unusually high estimated oral bioavailability of about 40%, so the human program used oral capsules.2 Preclinical no-observed-adverse-effect levels were at least 100 mg/kg/day oral in rats and 50 mg/kg/day in monkeys, supporting a wide safety margin.2

What is the evidence by indication?

This is the central, often-glossed-over story. Unlike most peptides marketed for body composition, AOD-9604 ran a genuine clinical program — and that program is precisely why its efficacy narrative collapses.

The weight-loss program comprised six randomized, double-blind, placebo-controlled trials (2001-2006, n=893): two IV pilots, two oral pilots, and two oral Phase IIb efficacy trials.1 In METAOD005 (12 weeks, ~300 obese adults), the 1 mg/day oral group lost on average about 2.6 to 2.8 kg versus roughly 0.8 kg on placebo — statistically significant in that trial, with a small improvement in glucose tolerance, and counter-intuitively higher doses were no better than 1 mg.3 But METAOD006 (24 weeks, 502 obese adults, oral 0.25-1 mg/day with diet and exercise) — the pivotal, larger, longer trial — failed: weight loss did not separate from placebo once an intensive diet-and-exercise regimen was added, and IGF-1 changes were non-significant.1 Metabolic Pharmaceuticals concluded the results "did not support the commercial viability of the drug as a treatment for obesity," discontinuing the program in 2007.1 For context, even the best early signal (~2 kg over placebo) is dwarfed by approved therapies — orlistat (~3-4 kg) and GLP-1/GIP agonists such as semaglutide (~15%) and tirzepatide (~21% of body weight).6

The joint-health reputation rests almost entirely on one preclinical study: a collagenase-induced knee-osteoarthritis model in 32 New Zealand white rabbits, where weekly intra-articular AOD-9604, especially combined with hyaluronic acid, enhanced cartilage regeneration versus saline.4 No human efficacy trial for cartilage or osteoarthritis has reported results, so any human joint-repair claim is extrapolation from a single rabbit study. The original positive rationale traces to mouse and in-vitro work showing increased fat oxidation and weight loss in obese mice.Heffernan and colleagues (2001, PMID 11673763) — preclinical, not human.5

What doses appear in the literature?

Reported strictly as information, not a protocol. The clinical-trial program used oral capsules and IV infusions — not subcutaneous injection.1 The IV pilots used 25-400 µg/kg single doses; the oral pilots used 9-54 mg single or daily doses for 7 days; the oral Phase IIb trials used 1-30 mg/day for 12 weeks (METAOD005) and 0.25-1 mg/day for 24 weeks (METAOD006), with the reported optimal weight-loss dose being 1 mg/day oral and no benefit above it.1 The preclinical osteoarthritis work used intra-articular 0.25 mg with or without hyaluronic acid, weekly, in rabbits.4 The subcutaneous ~250-500 µg/day "reconstitute lyophilized powder with bacteriostatic water" regimen circulating in the gray market is a wellness/clinic convention, not derived from the trial program — there are no human efficacy trials of subcutaneous AOD-9604.1 Because the molecule has high oral bioavailability (~40%) and a very short half-life, the original developers deliberately chose the oral route.2

How safe is AOD-9604?

Safety is AOD-9604's strongest data point. Across all six trials (n=893) the safety profile was described as "indistinguishable from placebo."1 Common adverse events were mild-to-moderate headache, diarrhea, flatulence and nausea, with gastrointestinal events increasing at the high 54 mg dose.1 There were no treatment-related serious adverse events or withdrawals; in METAOD005 five SAEs (including basal cell carcinoma, melanoma and breast cancer) were judged unrelated to treatment, and in METAOD006 SAEs were distributed similarly across placebo and active groups.1 IGF-1 showed no clinically significant change at any dose, oral glucose tolerance was unchanged with a favorable trend in impaired-glucose-tolerance subjects, and anti-AOD-9604 antibodies were undetectable.1

Because the molecule does not raise IGF-1 and showed no proliferative signal in cell assays, the GH-class concern about tumor promotion is theoretically lower than with full hGH — but long-term human carcinogenicity data simply do not exist.5 In practice the dominant real-world safety risk in 2026 is product, not molecule: gray-market "research-only" vials carry no guarantee of identity, purity, sterility or correct dose and are not pharmaceutical-grade.11 Pregnancy, lactation, pediatrics and active malignancy are untested and should be avoided, and no formal drug-interaction studies exist.

What is the FDA and WADA status in 2026?

AOD-9604 has never been FDA-approved for any indication, has no USP monograph, and is not an active ingredient in any approved drug — so it fails the baseline statutory criteria for pharmacy compounding.9 The timeline is precise: in September 2023 the FDA placed AOD-9604 (with several other peptides) in 503A Category 2 ("may present significant safety risks"), barring its use in compounding; in September 2024, following litigation and a settlement, the FDA removed it from Category 2 because the nominators withdrew their nominations — explicitly not an approval; and at the December 4, 2024 PCAC meeting the committee voted against including it on the 503A bulks list.10 In 2026 a political push (an HHS announcement on February 27, 2026) signaled intent to move roughly 14 Category-2 peptides, including AOD-9604, toward Category 1, with PCAC review slated for July 23-24, 2026. Commentators stress this is political intent, not a final FDA rule — it does not confer approval, validated dosing or proven benefit.1112 A self-affirmed industry-panel "Generally Recognized As Safe" (GRAS) food-ingredient determination also exists, but a GRAS self-determination is a far lower bar than drug approval and validates no therapeutic claim.13

For athletes the picture is unambiguous. AOD-9604 is explicitly named on the WADA Prohibited List under S2.2 — Growth Hormone, its analogues and fragments ("growth hormone fragments, e.g. AOD-9604 and hGH 176-191") — prohibited at all times, in and out of competition, and also captured by S0.7 It is detectable by anti-doping labs via a stable urinary metabolite and is banned by professional leagues such as MLB; any WADA-tested athlete should treat it as banned.8

Bottom line. AOD-9604 is the rare fat-loss peptide actually put to the human test — and the test is the point. Six RCTs establish, at Grade A confidence, that it is remarkably safe and that at studied oral doses it does not deliver clinically meaningful weight loss. What's proven is safety and a coherent (if unconfirmed) lipolytic mechanism; what's hyped is that it is an effective fat-loss agent. Regulatory facts here are current as of June 2026; the July 2026 PCAC outcome was pending at the time of writing and should be re-verified after that date. As of 2026 it remains not FDA-approved, not legally compoundable, and banned in sport.